Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

10 Sept 2020

Abstract excerpt

The treatment of older, unfit patients with acute myeloid leukemia (AML) is challenging. Based on preclinical data of Bruton tyrosine kinase expression/phosphorylation and ibrutinib cytotoxicity in AML blasts, we conducted a randomized phase 2 multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in unfit (ie, Hematopoietic Cell Transplantation Comorbidity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32915972
DOI: 10.1182/bloodadvances.2020002846

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDSPMID 32915972Read ↗

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).Semantic proximity Read ↗

CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agentsSemantic proximity Read ↗

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.Semantic proximity Read ↗

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid LeukemiaSemantic proximity Read ↗

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.Semantic proximity Read ↗

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AMLSemantic proximity Read ↗

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.Semantic proximity Read ↗

Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.Semantic proximity Read ↗

Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.Semantic proximity Read ↗

Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agentsSemantic proximity Read ↗

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.